New Strong Sell Stocks for May 26th
AMTB, ADMA and AHEXY have been added to the Zacks Rank #5 (Strong Sell) List on May 26, 2026.
Will the IG Market Challenges Affect ADMA Biologics Prospects in 2026?
ADMA cuts 2026 guidance after weak Bivigam sales and IG market pressure weigh on revenues amid rising competition and order volatility.
Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
ADMA shares plunge after the company cuts 2026 guidance, citing pricing pressure, rising competition and elevated IG channel inventories.
New Strong Sell Stocks for May 14th
ADMA, AMTB and APOG have been added to the Zacks Rank #5 (Strong Sell) List on May 14th, 2026.
New Strong Sell Stocks for May 11th
ADMA, APTV and ASTE have been added to the Zacks Rank #5 (Strong Sell) List on May 11th, 2026.
ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down
ADMA cuts its 2026 outlook after Q1 revenues slip amid IG market pressure, though Asceniv demand and margins stay strong.
ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?
ADMA stock in focus after FDA expands Asceniv's label to younger patients, boosting market reach and growth outlook amid rising demand.
Andrew Sather: Why Some Stock Buybacks Are Basically “Putting Money on Fire”
Stock buybacks have become one of the most misunderstood tools in corporate finance.
3 Biotech Stocks to Watch for Respectable Growth Beyond AI
Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher.
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA vs. Takeda: surging Asceniv demand boosts ADMA, but Takeda's diversified portfolio and stronger returns make it the steadier pick now.
